BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in
combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line
patients with metastatic colorectal cancer.